Acumen Pharma Says ALTITUDE-AD Missed Primary, Key Secondary Endpoints In Alzheimer's Study; Co. To Cease Clinical Development Of Sabirnetug, Preserve Cash And Explore Strategic Options
-- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) at 18 months
Acumen's Alzheimer's medicine didn't work as hoped in testing. When a drug fails, the company stops spending money on it and looks for new options.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.